Switch to:
Novo Nordisk A/S (NYSE:NVO)
Research and Development
$2,106 Mil (TTM As of Sep. 2016)

This is the expense the company spent on research and development. Novo Nordisk A/S's research and development for the three months ended in Sep. 2016 was $521 Mil. Its research and development for the trailing twelve months (TTM) ended in Sep. 2016 was $2,106 Mil.


Definition

This is the expense the company spent on research and development.

Novo Nordisk A/S Research & Development for the trailing twelve months (TTM) ended in Sep. 2016 was 588.647307748 (Dec. 2015 ) + 493.237392888 (Mar. 2016 ) + 503.096209032 (Jun. 2016 ) + 520.861575538 (Sep. 2016 ) = $2,106 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Novo Nordisk A/S Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
Research & Development 1,1191,6691,4251,5401,7031,7031,9162,1562,2801,986

Novo Nordisk A/S Quarterly Data

Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16
Research & Development 561633640471457495589493503521
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK